title: Anti-CD22 CAR Therapy Leads to ALL Remissions.
abstract: In a first-in-human trial of an anti-CD22 chimeric antigen receptor T-cell therapy in children and young adults with relapsed and refractory acute lymphocytic leukemia, researchers found that the immunotherapeutic approach was not only feasible and safe, but also effective, leading to remissions in most patients. Infusions of higher numbers of T cells correlated with improved responses.
mesh_terms: D064987:Cell- and Tissue-Based Therapy; D002648:Child; D017321:Clinical Trials, Phase I as Topic; D005260:Female; D006801:Humans; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology / Q000628:therapy*; D011948:Receptors, Antigen, T-Cell / Q000378:metabolism*; D012074:Remission Induction; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology / Q000637:transplantation*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: C497867:CD22 protein, human; C000598123:CTL019 chimeric antigen receptor; D011948:Receptors, Antigen, T-Cell; D051918:Sialic Acid Binding Ig-like Lectin 2